Thiazolidinediones or TZD drugs which are widely used in diabetes treatment have shown serious effects on the kidneys.

"TZDs usually increase body weight by several kilograms," said George Seki of the University of Tokyo.
"However, TZDs sometimes cause massive volume expansion, resulting in heart failure," he added.
Now his team reports that those negative consequences arise in more than one way.
TZDs act on a hormone receptor known as peroxisome proliferator-activated receptor ? (PPAR?). PPAR? is a master gene of fat cell biology and differentiation, Seki explained, making it an ideal target for diabetes treatment.
Seki's team has found that TZDs also have direct effects on channels in the kidney known as the proximal tubules.
Advertisement
The researchers confirm that those effects occur regardless of whether PPAR? can bind DNA to influence the activity of other genes.
Advertisement
Source-ANI